Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBID vs DVLP, CSTF, BLMS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neorich Biopharma Tech Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neorich Biopharma Tech Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neorich Biopharma Tech Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Neorich Biopharma Tech Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neorich Biopharma Tech Co (PHBID) has a OCF Margin % of 800.00% as of Jun. 2023. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's OCF Margin % too high?
Neorich Biopharma Tech Co's current OCF Margin % is 800.00%. The Drug Manufacturers industry median OCF Margin % is 9.77. Neorich Biopharma Tech Co's value of 800.00% is 8088.3% above this industry median.
How does Neorich Biopharma Tech Co's OCF Margin % compare to DVLP and CSTF?
Neorich Biopharma Tech Co's OCF Margin % of 800.00% can be compared against companies in the Drug Manufacturers industry. The industry median OCF Margin % is 9.77. Neorich Biopharma Tech Co's value of 800.00% is 8088.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.77, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neorich Biopharma Tech Co's current OCF Margin % of 800.00% is 8088.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Neorich Biopharma Tech Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neorich Biopharma Tech Co's current OCF Margin % is 800.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current OCF Margin % of 800.00%. The current OCF Margin % is 800.00% and 8088.3% above the Drug Manufacturers industry median of 9.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current OCF Margin % is 800.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBID has been successfully added to your 
